Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Safety and Dose-Escalation of AV-951 plus Everolimus in Metastatic Renal Cell Carcinoma
2009-009461-33Phase 2Terminated
- Sponsor
- AISAR
- Start
- Apr 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivozanib and everolimus in metastatic renal cell carcinoma (mRCC), sponsored by AISAR. Primary endpoints: Safety, tolerability, and maximum tolerated dose of AV-951 plus everolimus and Pharmacokinetics of AV-951 and everolimus alone and in combination. Started Apr 2009; status: terminated.
02
Drugs
tivozanibeverolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2009-009461-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009461-33.